PHASE II AERX HCQ PROGRAM ANNOUNCED

Aradigm and APT Pharmaceuticals announced the program advancement of APT's proprietary formulation of hydroxychloroquine into Phase II clinical trials. APT and Aradigm are developing this aerosolized formulation of the anti-inflammatory agent HCQ in Aradigm's AERx pulmonary delivery system as a new class of treatment for asthma and chronic obstructive pulmonary disease.

As part of the APT-funded program, Aradigm will source the active pharmaceutical ingredient, conduct the formulation development of the drug product, manufacture clinical supplies and execute regulatory and clinical development. Aradigm and APT recently completed a Phase I study in healthy volunteers, which determined that AERx delivered HCQ had a favorable safety and tolerability profile that enabled progression into the Phase II clinical program.